Tokyo Tape
Sign in
← Kohjin Bio

Annual report

177A.TEDINET S100TX40
Period2023-04-01 → 2024-03-31
Filed2024-06-28
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 120
MetricValuePeriodScopeSource row
Revenue¥4.8bn2023-04-01 → 2024-03-31Cons.Net sales
Revenue¥4.7bn2022-04-01 → 2023-03-31Cons.Net sales
Revenue¥3.9bn2021-04-01 → 2022-03-31dCons.Net sales (5-year summary)
Operating income¥597m2023-04-01 → 2024-03-31Cons.Operating income
Operating income¥1.3bn2022-04-01 → 2023-03-31Cons.Operating income
Ordinary income¥636m2023-04-01 → 2024-03-31Cons.Ordinary income
Ordinary income¥1.2bn2022-04-01 → 2023-03-31Cons.Ordinary income
Ordinary income¥918m2021-04-01 → 2022-03-31dCons.Ordinary income loss (5-year summary)
Profit before tax¥636m2023-04-01 → 2024-03-31Cons.Income before income taxes
Profit before tax¥1.2bn2022-04-01 → 2023-03-31Cons.Income before income taxes
Net income (owners)¥385m2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥830m2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥588m2021-04-01 → 2022-03-31dCons.Profit loss attributable to owners of parent (5-year summary)
Net income¥385m2023-04-01 → 2024-03-31Cons.Profit loss
Net income¥830m2022-04-01 → 2023-03-31Cons.Profit loss
Total assets¥6.6bnat 2024-03-31Cons.Assets
Total assets¥6.1bnat 2023-03-31Cons.Assets
Total assets¥5.6bnat 2022-03-31dCons.Total assets (5-year summary)
Total liabilities¥3.2bnat 2024-03-31Cons.Liabilities
Total liabilities¥3.1bnat 2023-03-31Cons.Liabilities
Net assets / equity¥3.3bnat 2024-03-31Cons.Net assets
Net assets / equity¥3.0bnat 2023-03-31Cons.Net assets
Net assets / equity¥2.2bnat 2022-03-31dCons.Net assets
Cash and deposits¥1.7bnat 2024-03-31Cons.Cash and deposits
Cash and deposits¥1.5bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥1.7bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥1.5bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥1.7bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow¥824m2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities
Operating cash flow¥461m2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities
Operating cash flow¥763m2021-04-01 → 2022-03-31dCons.Net cash provided by used in operating activities (5-year summary)
Investing cash flow−¥577m2023-04-01 → 2024-03-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥575m2022-04-01 → 2023-03-31Cons.Net cash provided by used in investment activities
Investing cash flow¥83m2021-04-01 → 2022-03-31dCons.Net cash provided by used in investing activities (5-year summary)
Financing cash flow−¥1m2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities
Financing cash flow−¥172m2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities
Financing cash flow−¥360m2021-04-01 → 2022-03-31dCons.Net cash provided by used in financing activities (5-year summary)
EPS (basic)¥92.432023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥199.232022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥173.52021-04-01 → 2022-03-31dCons.Basic earnings loss per share (5-year summary)
Net assets per share¥802.5at 2024-03-31Cons.Net assets per share (5-year summary)
Net assets per share¥724.57at 2023-03-31Cons.Net assets per share (5-year summary)
Net assets per share¥532.27at 2022-03-31dCons.Net assets per share (5-year summary)
Equity ratio50.7%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio49.2%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio39.6%at 2022-03-31dCons.Equity to asset ratio (5-year summary)
ROE12.1%2023-04-01 → 2024-03-31Cons.Rate of return on equity (5-year summary)
ROE31.7%2022-04-01 → 2023-03-31Cons.Rate of return on equity (5-year summary)
ROE31.2%2021-04-01 → 2022-03-31dCons.Rate of return on equity (5-year summary)
Employees159at 2024-03-31Cons.Number of employees
Employees139at 2023-03-31Cons.Number of employees
Employees130at 2022-03-31dCons.Number of employees
Revenue¥4.4bn2023-04-01 → 2024-03-31StandaloneNet sales
Revenue¥4.4bn2022-04-01 → 2023-03-31StandaloneNet sales
Revenue¥3.6bn2021-04-01 → 2022-03-31dStandaloneNet sales (5-year summary)
Revenue¥3.3bn2020-04-01 → 2021-03-31dStandaloneNet sales (5-year summary)
Revenue¥2.8bn2019-04-01 → 2020-03-31dStandaloneNet sales (5-year summary)
Operating income¥445m2023-04-01 → 2024-03-31StandaloneOperating income
Operating income¥1.1bn2022-04-01 → 2023-03-31StandaloneOperating income
Ordinary income¥409m2023-04-01 → 2024-03-31StandaloneOrdinary income
Ordinary income¥1.1bn2022-04-01 → 2023-03-31StandaloneOrdinary income
Ordinary income¥842m2021-04-01 → 2022-03-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥666m2020-04-01 → 2021-03-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥456m2019-04-01 → 2020-03-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax¥423m2023-04-01 → 2024-03-31StandaloneIncome before income taxes
Profit before tax¥1.1bn2022-04-01 → 2023-03-31StandaloneIncome before income taxes
Net income¥212m2023-04-01 → 2024-03-31StandaloneProfit loss
Net income¥751m2022-04-01 → 2023-03-31StandaloneProfit loss
Net income¥564m2021-04-01 → 2022-03-31dStandaloneNet income loss (5-year summary)
Net income¥685m2020-04-01 → 2021-03-31dStandaloneNet income loss (5-year summary)
Net income¥303m2019-04-01 → 2020-03-31dStandaloneNet income loss (5-year summary)
Total assets¥6.0bnat 2024-03-31StandaloneAssets
Total assets¥5.8bnat 2023-03-31StandaloneAssets
Total assets¥5.3bnat 2022-03-31dStandaloneTotal assets (5-year summary)
Total assets¥4.8bnat 2021-03-31dStandaloneTotal assets (5-year summary)
Total assets¥4.2bnat 2020-03-31dStandaloneTotal assets (5-year summary)
Total liabilities¥3.2bnat 2024-03-31StandaloneLiabilities
Total liabilities¥3.0bnat 2023-03-31StandaloneLiabilities
Net assets / equity¥2.8bnat 2024-03-31StandaloneNet assets
Net assets / equity¥2.7bnat 2023-03-31StandaloneNet assets
Net assets / equity¥2.0bnat 2022-03-31dStandaloneNet assets
Net assets / equity¥1.4bnat 2021-03-31dStandaloneNet assets (5-year summary)
Net assets / equity¥748mat 2020-03-31dStandaloneNet assets (5-year summary)
Cash and deposits¥1.2bnat 2024-03-31StandaloneCash and deposits
Cash and deposits¥1.0bnat 2023-03-31StandaloneCash and deposits
EPS (basic)¥50.92023-04-01 → 2024-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥180.372022-04-01 → 2023-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥166.592021-04-01 → 2022-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥2,023.852020-04-01 → 2021-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥896.592019-04-01 → 2020-03-31dStandaloneBasic earnings loss per share (5-year summary)
Dividend per share¥142023-04-01 → 2024-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥192022-04-01 → 2023-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥1002021-04-01 → 2022-03-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥1002020-04-01 → 2021-03-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥452019-04-01 → 2020-03-31dStandaloneDividend paid per share (5-year summary)
Net assets per share¥683.18at 2024-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥651.21at 2023-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥480.9at 2022-03-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥4,121.96at 2021-03-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥2,105.69at 2020-03-31dStandaloneNet assets per share (5-year summary)
Equity ratio47.2%at 2024-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio47.2%at 2023-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio38.0%at 2022-03-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio28.9%at 2021-03-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio17.3%at 2020-03-31dStandaloneEquity to asset ratio (5-year summary)
ROE7.6%2023-04-01 → 2024-03-31StandaloneRate of return on equity (5-year summary)
ROE31.9%2022-04-01 → 2023-03-31StandaloneRate of return on equity (5-year summary)
ROE33.2%2021-04-01 → 2022-03-31dStandaloneRate of return on equity (5-year summary)
ROE64.7%2020-04-01 → 2021-03-31dStandaloneRate of return on equity (5-year summary)
ROE54.7%2019-04-01 → 2020-03-31dStandaloneRate of return on equity (5-year summary)
Shares issued4,165,000at 2024-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued4,165,000at 2023-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued416,500at 2022-03-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued338,500at 2021-03-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued338,500at 2020-03-31dStandaloneTotal number of issued shares (5-year summary)
Employees135at 2024-03-31StandaloneNumber of employees
Employees117at 2023-03-31StandaloneNumber of employees
Employees108at 2022-03-31dStandaloneNumber of employees
Employees98at 2021-03-31dStandaloneNumber of employees
Employees101at 2020-03-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 42
SegmentItemPeriodValue
Reconciling Itemsreconcilingdepreciation2023-04-01 → 2024-03-31¥15m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2024-03-31−¥415m
Cell Process Businessreportable segmentdepreciation2023-04-01 → 2024-03-31¥114m
Cell Process Businessreportable segmentemployeesat 2024-03-3136 pure
Cell Process Businessreportable segmentrevenue2023-04-01 → 2024-03-31¥1.2bn
Cell Process Businessreportable segmentrevenue external2023-04-01 → 2024-03-31¥1.2bn
Cell Process Businessreportable segmentsegment profit2023-04-01 → 2024-03-31¥472m
Microbiological Businessreportable segmentdepreciation2023-04-01 → 2024-03-31¥100m
Microbiological Businessreportable segmentemployeesat 2024-03-3150 pure
Microbiological Businessreportable segmentrevenue2023-04-01 → 2024-03-31¥1.7bn
Microbiological Businessreportable segmentrevenue external2023-04-01 → 2024-03-31¥1.7bn
Microbiological Businessreportable segmentsegment profit2023-04-01 → 2024-03-31−¥69m
Tissue Culture Businessreportable segmentdepreciation2023-04-01 → 2024-03-31¥69m
Tissue Culture Businessreportable segmentemployeesat 2024-03-3159 pure
Tissue Culture Businessreportable segmentrevenue2023-04-01 → 2024-03-31¥1.9bn
Tissue Culture Businessreportable segmentrevenue external2023-04-01 → 2024-03-31¥1.9bn
Tissue Culture Businessreportable segmentsegment profit2023-04-01 → 2024-03-31¥609m
—segment totaldepreciation2023-04-01 → 2024-03-31¥284m
—segment totalrevenue2023-04-01 → 2024-03-31¥4.8bn
—segment totalrevenue external2023-04-01 → 2024-03-31¥4.8bn
—segment totalsegment profit2023-04-01 → 2024-03-31¥1.0bn
Reconciling Itemsreconcilingdepreciation2022-04-01 → 2023-03-31¥13m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2023-03-31−¥353m
Cell Process Businessreportable segmentdepreciation2022-04-01 → 2023-03-31¥20m
Cell Process Businessreportable segmentrevenue2022-04-01 → 2023-03-31¥697m
Cell Process Businessreportable segmentrevenue external2022-04-01 → 2023-03-31¥697m
Cell Process Businessreportable segmentsegment profit2022-04-01 → 2023-03-31¥281m
Microbiological Businessreportable segmentdepreciation2022-04-01 → 2023-03-31¥85m
Microbiological Businessreportable segmentrevenue2022-04-01 → 2023-03-31¥2.4bn
Microbiological Businessreportable segmentrevenue external2022-04-01 → 2023-03-31¥2.4bn
Microbiological Businessreportable segmentsegment profit2022-04-01 → 2023-03-31¥818m
Tissue Culture Businessreportable segmentdepreciation2022-04-01 → 2023-03-31¥46m
Tissue Culture Businessreportable segmentrevenue2022-04-01 → 2023-03-31¥1.6bn
Tissue Culture Businessreportable segmentrevenue external2022-04-01 → 2023-03-31¥1.6bn
Tissue Culture Businessreportable segmentsegment profit2022-04-01 → 2023-03-31¥522m
—segment totaldepreciation2022-04-01 → 2023-03-31¥151m
—segment totalrevenue2022-04-01 → 2023-03-31¥4.7bn
—segment totalrevenue external2022-04-01 → 2023-03-31¥4.7bn
—segment totalsegment profit2022-04-01 → 2023-03-31¥1.6bn
Cell Process Businessreportable segmentemployeesat 2024-03-3136 pure
Microbiological Businessreportable segmentemployeesat 2024-03-3145 pure
Tissue Culture Businessreportable segmentemployeesat 2024-03-3140 pure

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,335
ItemContextValueUnit
Name major shareholdersCurrentYearInstant_No3MajorShareholdersMember
Original text (Japanese)オリエンタル酵母工業㈱
Address major shareholdersCurrentYearInstant_No3MajorShareholdersMember
Original text (Japanese)東京都板橋区小豆沢３-６-10
Name major shareholdersCurrentYearInstant_No4MajorShareholdersMember
Original text (Japanese)コージンバイオ従業員持株会
Address major shareholdersCurrentYearInstant_No4MajorShareholdersMember
Original text (Japanese)埼玉県坂戸市千代田５-１-３
Name major shareholdersCurrentYearInstant_No5MajorShareholdersMember
Original text (Japanese)富士フイルム和光純薬㈱
Address major shareholdersCurrentYearInstant_No5MajorShareholdersMember
Original text (Japanese)大阪府大阪市中央区道修町３-１-２
Name major shareholdersCurrentYearInstant_No6MajorShareholdersMember
Original text (Japanese)渡辺　恒美
Address major shareholdersCurrentYearInstant_No6MajorShareholdersMemberNonthaburi Thailand
Name major shareholdersCurrentYearInstant_No7MajorShareholdersMember
Original text (Japanese)SMBC事業開発１号投資事業有限責任組合
Address major shareholdersCurrentYearInstant_No7MajorShareholdersMember
Original text (Japanese)東京都中央区八重洲１-３-４
Name major shareholdersCurrentYearInstant_No8MajorShareholdersMember
Original text (Japanese)埼玉りそな銀２号投資事業組合
Address major shareholdersCurrentYearInstant_No8MajorShareholdersMember
Original text (Japanese)東京都江東区木場１-５-25
Name major shareholdersCurrentYearInstant_No9MajorShareholdersMember
Original text (Japanese)コスモ・バイオ㈱
Address major shareholdersCurrentYearInstant_No9MajorShareholdersMember
Original text (Japanese)東京都江東区東陽２-２-20
Name major shareholdersCurrentYearInstant_No10MajorShareholdersMember
Original text (Japanese)ニプロ㈱
Address major shareholdersCurrentYearInstant_No10MajorShareholdersMember
Original text (Japanese)大阪府摂津市千里丘新町３-26
Issued shares voting rights (text)FilingDateInstantText · Plus
Description issued shares voting rightsCurrentYearInstant_SharesWithNoVotingRightsMember－
Description issued shares voting rightsCurrentYearInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember－
Description issued shares voting rightsCurrentYearInstant_SharesWithRestrictedVotingRightsOtherMember－
Description issued shares voting rightsCurrentYearInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember－
Description issued shares voting rightsCurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember
Original text (Japanese)権利内容に何ら限定のない当社における標準となる株式であり、単元株式数は100株であります。
Description issued shares voting rightsCurrentYearInstant_OrdinarySharesSharesLessThanOneUnitMember－
Treasury shares etc (text)FilingDateInstantText · Plus
Classes of shares etc (text)FilingDateInstantText · Plus
Acquisitions by resolution of shareholders meeting (text)FilingDateInstantText · Plus
Acquisitions by resolution of board of directors meeting (text)FilingDateInstantText · Plus
Acquisitions not based on resolution of shareholders meeting or board of directors meeting (text)FilingDateInstantText · Plus
Disposals or holding of acquired treasury shares (text)FilingDateInstantText · Plus
Dividend policy (text)FilingDateInstantText · Plus
Date of resolution dividends of surplusFilingDateInstant_Row1Member2024-06-28
Resolution dividends of surplusFilingDateInstant_Row1Member
Original text (Japanese)定時株主総会決議
Overview of corporate governance (text)FilingDateInstantText · Plus
Corporate governance company with corporate auditors (text)FilingDateInstantText · Plus
Information about officers (text)FilingDateInstantText · Plus
Official title or position information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E38689-000NakamuraTakahitoMember
Original text (Japanese)代表取締役社長
Name information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E38689-000NakamuraTakahitoMember
Original text (Japanese)中村　孝人
Date of birth information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E38689-000NakamuraTakahitoMember1949-05-23
Career summary information about directors and corporate auditors (text)FilingDateInstant_jpcrp030000-asr_E38689-000NakamuraTakahitoMemberText · Plus
Term of office information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E38689-000NakamuraTakahitoMember
Original text (Japanese)（注）３
Official title or position information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E38689-000NakamuraYuichiMember
Original text (Japanese)専務取締役営業統括
Name information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E38689-000NakamuraYuichiMember
Original text (Japanese)中村　雄一
Date of birth information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E38689-000NakamuraYuichiMember1978-08-29
Career summary information about directors and corporate auditors (text)FilingDateInstant_jpcrp030000-asr_E38689-000NakamuraYuichiMemberText · Plus
Term of office information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E38689-000NakamuraYuichiMember
Original text (Japanese)（注）３
Official title or position information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E38689-000TsuihijiHisayoshiMember
Original text (Japanese)取締役研究・細胞加工統括
Name information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E38689-000TsuihijiHisayoshiMember
Original text (Japanese)對比地　久義
Date of birth information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E38689-000TsuihijiHisayoshiMember1975-07-01
Career summary information about directors and corporate auditors (text)FilingDateInstant_jpcrp030000-asr_E38689-000TsuihijiHisayoshiMemberText · Plus
Term of office information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E38689-000TsuihijiHisayoshiMember
Original text (Japanese)（注）３

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 24 of 24 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2024-03-31pass rounding
balance sheet identitynon_consolidated 2023-03-31pass
balance sheet identitynon_consolidated 2024-03-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsnon_consolidated 2022-03-31pass
statement vs summary · net assetsnon_consolidated 2023-03-31pass
statement vs summary · net assetsnon_consolidated 2024-03-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2023-03-31pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2024-03-31pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2023-03-31pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2024-03-31pass
statement vs summary · revenueconsolidated 2022-04-01/2023-03-31pass
statement vs summary · revenueconsolidated 2023-04-01/2024-03-31pass
statement vs summary · revenuenon_consolidated 2022-04-01/2023-03-31pass
statement vs summary · revenuenon_consolidated 2023-04-01/2024-03-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsnon_consolidated 2023-03-31pass
statement vs summary · total assetsnon_consolidated 2024-03-31pass